1-deamino-/4-valine-8-D-arginine/-vasopressin (dVDAVP), a new synthetic vasopressin analog for treating diabetes insipidus.

Abstract

The effects of LVP, dDAVP, and dVDAVP on the water excretion of 14 vasopressin-sensitive and 2 ADH-resistant patients with diabetes insipidus were studied and compared. Findings showed that dDAVP and dVDAVP decreased the diuresis of all ADH-sensitive patients, and in those with diabetes insipidus, more markedly (7.6-fold) and for a longer duration (3.3-fold) than did LVP. From a comparison of the results, dVDAVP is at present one of the most effective preparations for reduction of polyuria in patients with ADH-sensitive diabetes insipidus.

• Authors: F A László, L Czakó
• Journal: International journal of clinical pharmacology, therapy, and toxicology (Int J Clin Pharmacol Ther Toxicol) Vol. 20 Issue 1 Pg. 39-43 (Jan 1982) ISSN: 0174-4879 [Print] Germany
• PMID: 7056603 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Arginine Vasopressin
• Lypressin
• vasopressin, 1-deamino-4-Val-8-Arg-
• Deamino Arginine Vasopressin
• Valine

Topics

• Adult
• Aged
• Arginine Vasopressin (analogs & derivatives)
• Deamino Arginine Vasopressin (analogs & derivatives, therapeutic use)
• Diabetes Mellitus (drug therapy)
• Diuresis (drug effects)
• Female
• Humans
• Lypressin (pharmacology, therapeutic use)
• Male
• Middle Aged
• Valine (analogs & derivatives, therapeutic use)